{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:32:37Z","timestamp":1793892757422,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,11,20]]},"DOI":"10.1038\/s41416-026-03580-1","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:51:45Z","timestamp":1786956705000},"page":"1694-1704","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CTPS1 promotes lung adenocarcinoma progression as a targetable vulnerability"],"prefix":"10.1038","volume":"135","author":[{"given":"Hui","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5651-8608","authenticated-orcid":false,"given":"Wenhao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0704-8782","authenticated-orcid":false,"given":"Dongdong","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0014-8025","authenticated-orcid":false,"given":"Guangshun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"3580_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3580_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","volume":"10","author":"Q Huang","year":"2025","unstructured":"Huang Q, Li Y, Huang Y, Wu J, Bao W, Xue C, et al. Advances in molecular pathology and therapy of non-small cell lung cancer. Signal Transduct Target Ther. 2025;10:186.","journal-title":"Signal Transduct Target Ther"},{"key":"3580_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LEL Hendriks","year":"2024","unstructured":"Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, et al. Non-small cell lung cancer. Nat Rev Dis Primers. 2024;10:71.","journal-title":"Nat Rev Dis Primers"},{"key":"3580_CR4","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S1470-2045(23)00444-8","volume":"24","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023;24:1206\u201318.","journal-title":"Lancet Oncol"},{"key":"3580_CR5","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.2174\/0929867326666190222183219","volume":"27","author":"SS Singh","year":"2020","unstructured":"Singh SS, Dahal A, Shrestha L, Jois SD. Genotype driven therapy for non-small cell lung cancer: resistance, pan inhibitors and immunotherapy. Curr Med Chem. 2020;27:5274\u2013316.","journal-title":"Curr Med Chem"},{"key":"3580_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41\u201350.","journal-title":"N Engl J Med"},{"key":"3580_CR7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725\u201337.","journal-title":"Br J Cancer"},{"key":"3580_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.lungcan.2019.09.019","volume":"137","author":"C Mehlman","year":"2019","unstructured":"Mehlman C, Cadranel J, Rousseau-Bussac G, Lacave R, Pujals A, Girard N, et al. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study. Lung Cancer. 2019;137:149\u201356.","journal-title":"Lung Cancer"},{"key":"3580_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","volume":"7","author":"JJ Lin","year":"2017","unstructured":"Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov. 2017;7:137\u201355.","journal-title":"Cancer Discov"},{"key":"3580_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27\u201347.","journal-title":"Cell Metab"},{"key":"3580_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden MG, DeBerardinis RJ. Understanding the Intersections between Metabolism and Cancer Biology. Cell. 2017;168:657\u201369.","journal-title":"Cell"},{"key":"3580_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"3580_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.semcdb.2012.02.002","volume":"23","author":"D Daye","year":"2012","unstructured":"Daye D, Wellen KE. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol. 2012;23:362\u20139.","journal-title":"Semin Cell Dev Biol"},{"key":"3580_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.oooo.2014.04.003","volume":"118","author":"T Ogawa","year":"2014","unstructured":"Ogawa T, Washio J, Takahashi T, Echigo S, Takahashi N. Glucose and glutamine metabolism in oral squamous cell carcinoma: insight from a quantitative metabolomic approach. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118:218\u201325.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"3580_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","volume":"23","author":"NJ Mullen","year":"2023","unstructured":"Mullen NJ, Singh PK. Nucleotide metabolism: a pan-cancer metabolic dependency. Nat Rev Cancer. 2023;23:275\u201394.","journal-title":"Nat Rev Cancer"},{"key":"3580_CR16","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.trecan.2023.04.008","volume":"9","author":"DD Shi","year":"2023","unstructured":"Shi DD, Savani MR, Abdullah KG, McBrayer SK. Emerging roles of nucleotide metabolism in cancer. Trends Cancer. 2023;9:624\u201335.","journal-title":"Trends Cancer"},{"key":"3580_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nature13386","volume":"510","author":"E Martin","year":"2014","unstructured":"Martin E, Palmic N, Sanquer S, Lenoir C, Hauck F, Mongellaz C, et al. CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. Nature. 2014;510:288\u201392.","journal-title":"Nature"},{"key":"3580_CR18","doi-asserted-by":"publisher","first-page":"e202302066","DOI":"10.26508\/lsa.202302066","volume":"6","author":"N Minet","year":"2023","unstructured":"Minet N, Boschat AC, Lane R, Laughton D, Beer P, Asnagli H, et al. Differential roles of CTP synthetases CTPS1 and CTPS2 in cell proliferation. Life Sci Alliance. 2023;6:e202302066.","journal-title":"Life Sci Alliance"},{"key":"3580_CR19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107968118","volume":"118","author":"EM Lynch","year":"2021","unstructured":"Lynch EM, DiMattia MA, Albanese S, van Zundert GCP, Hansen JM, Quispe JD, et al. Structural basis for isoform-specific inhibition of human CTPS1. Proc Natl Acad Sci USA. 2021;118:e2107968118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3580_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33001","volume":"10","author":"H Huang","year":"2024","unstructured":"Huang H, Chen Y, Li Y, Zheng X, Shu L, Tian L, et al. Cytidine triphosphate synthase 1-mediated metabolic reprogramming promotes proliferation and drug resistance in multiple myeloma. Heliyon. 2024;10:e33001.","journal-title":"Heliyon"},{"key":"3580_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03206-5","volume":"20","author":"Y Lin","year":"2022","unstructured":"Lin Y, Zhang J, Li Y, Guo W, Chen L, Chen M, et al. CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1. J Transl Med. 2022;20:17.","journal-title":"J Transl Med"},{"key":"3580_CR22","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1080\/15384101.2022.2105084","volume":"21","author":"F Wu","year":"2022","unstructured":"Wu F, Mao Y, Ma T, Wang X, Wei H, Wang T, et al. CTPS1 inhibition suppresses proliferation and migration in colorectal cancer cells. Cell Cycle. 2022;21:2563\u201374.","journal-title":"Cell Cycle"},{"key":"3580_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/bjh.18878","volume":"202","author":"JH Liang","year":"2023","unstructured":"Liang JH, Ren YM, Du KX, Gao R, Duan ZW, Guo JR, et al. MYC-induced cytidine metabolism regulates survival and drug resistance via cGas-STING pathway in mantle cell lymphoma. Br J Haematol. 2023;202:550\u201365.","journal-title":"Br J Haematol"},{"key":"3580_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41375-023-02071-z","volume":"38","author":"C Pfeiffer","year":"2024","unstructured":"Pfeiffer C, Grandits AM, Asnagli H, Schneller A, Huber J, Zojer N, et al. CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1. Leukemia. 2024;38:181\u201392.","journal-title":"Leukemia"},{"key":"3580_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70016","volume":"8","author":"R Durand","year":"2024","unstructured":"Durand R, Bellanger C, Descamps G, Dousset C, Ma\u00efga S, Derrien J, et al. Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells. Hemasphere. 2024;8:e70016.","journal-title":"Hemasphere"},{"key":"3580_CR26","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.3324\/haematol.2023.284345","volume":"109","author":"R Durand","year":"2024","unstructured":"Durand R, Bellanger C, Kervo\u00eblen C, Tessoulin B, Dousset C, Menoret E, et al. Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma. Haematologica. 2024;109:2574\u201384.","journal-title":"Haematologica"},{"key":"3580_CR27","doi-asserted-by":"publisher","first-page":"e864","DOI":"10.1097\/HS9.0000000000000864","volume":"7","author":"H Asnagli","year":"2023","unstructured":"Asnagli H, Minet N, Pfeiffer C, Hoeben E, Lane R, Laughton D, et al. CTP synthase 1 is a novel therapeutic target in lymphoma. Hemasphere. 2023;7:e864.","journal-title":"Hemasphere"},{"key":"3580_CR28","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41586-025-08835-0","volume":"641","author":"Y Tian","year":"2025","unstructured":"Tian Y, Feng T, Zhang J, Meng Q, Zhan W, Tang M, et al. Histone H1 deamidation facilitates chromatin relaxation for DNA repair. Nature. 2025;641:779\u201387.","journal-title":"Nature"},{"key":"3580_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cell.2020.05.043","volume":"182","author":"JY Xu","year":"2020","unstructured":"Xu JY, Zhang C, Wang X, Zhai L, Ma Y, Mao Y, et al. Integrative Proteomic Characterization of Human Lung Adenocarcinoma. Cell. 2020;182:245\u201361.","journal-title":"Cell"},{"key":"3580_CR30","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.ccell.2025.07.011","volume":"43","author":"S Satpathy","year":"2025","unstructured":"Satpathy S, Clark NM, Chen YJ, Hosseini N, Chang YH, Hsiao Y, et al. Clinical Proteomic Tumor Analysis Consortium. Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures. Cancer Cell. 2025;43:1731\u201357.e17.","journal-title":"Cancer Cell"},{"key":"3580_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2020-138436","volume":"136","author":"A Parker","year":"2020","unstructured":"Parker A. STP938, a Novel, Potent and Selective Inhibitor of CTP Synthase 1 (CTPS1) Is a Targeted Therapy Specifically Blocking De Novo Nucleotide Synthesis in Lymphomas and Leukemias. Blood. 2020;136:31.","journal-title":"Blood"},{"key":"3580_CR32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature10098","volume":"473","author":"B Schwanh\u00e4usser","year":"2011","unstructured":"Schwanh\u00e4usser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature. 2011;473:337\u201342.","journal-title":"Nature"},{"key":"3580_CR33","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, et al. iProX: an integrated proteome resource. Nucleic Acids Res. 2019;47:D1211\u2013D1217.","journal-title":"Nucleic Acids Res"},{"key":"3580_CR34","doi-asserted-by":"publisher","first-page":"D1522","DOI":"10.1093\/nar\/gkab1081","volume":"50","author":"T Chen","year":"2022","unstructured":"Chen T, Ma J, Liu Y, Chen Z, Xiao N, Lu Y, et al. iProX in 2021: connecting proteomics data sharing with big data. Nucleic Acids Res. 2022;50:D1522\u2013D1527.","journal-title":"Nucleic Acids Res"},{"key":"3580_CR35","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.celrep.2016.12.061","volume":"18","author":"M Momcilovic","year":"2017","unstructured":"Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, et al. Targeted Inhibition of EGFR and Glutaminase induces metabolic crisis in EGFR mutant lung cancer. Cell Rep. 2017;18:601\u201310.","journal-title":"Cell Rep"},{"key":"3580_CR36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/ncb3124","volume":"17","author":"LK Boroughs","year":"2015","unstructured":"Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17:351\u20139.","journal-title":"Nat Cell Biol"},{"key":"3580_CR37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15:405\u201314.","journal-title":"Nat Rev Immunol"},{"key":"3580_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03963-z","volume":"25","author":"K Zolfaghari","year":"2025","unstructured":"Zolfaghari K, Yazdi M, Mohammadioun S, Tajafrooz F, Malekfarnood H, Saleki K, et al. Interferon signaling and STING pathway in head and neck cancers: unlocking immune secrets and therapeutic frontiers. Cancer Cell Int. 2025;25:324.","journal-title":"Cancer Cell Int"},{"key":"3580_CR39","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.3390\/cancers17213480","volume":"17","author":"V Bonuomo","year":"2025","unstructured":"Bonuomo V, Dogliotti I, Masucci S, Grano S, Savi A, Frolli A, et al. The Dual Role of Interferon Signaling in Myeloproliferative Neoplasms: Pathogenesis and Targeted Therapeutics. Cancers (Basel). 2025;17:3480.","journal-title":"Cancers (Basel)"},{"key":"3580_CR40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cytogfr.2025.12.008","volume":"87","author":"D Kasat","year":"2026","unstructured":"Kasat D, Hidalgo S, Wang L, Bui JD, Dosset M. Interferons as therapeutic orchestrators of cancer stem cell plasticity and therapy response. Cytokine Growth Factor Rev. 2026;87:102\u201312.","journal-title":"Cytokine Growth Factor Rev"},{"key":"3580_CR41","doi-asserted-by":"publisher","DOI":"10.4110\/in.2025.25.e8","volume":"25","author":"TH Chang","year":"2025","unstructured":"Chang TH, Ho PC. Interferon-driven Metabolic Reprogramming and Tumor Microenvironment Remodeling. Immune Netw. 2025;25:e8.","journal-title":"Immune Netw"},{"key":"3580_CR42","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/10985549.2025.2497817","volume":"45","author":"A Mabry","year":"2025","unstructured":"Mabry A, Kuzmicki CE, O\u2019Brien A, Maggi LB Jr, Weber JD. Elevated Type I Interferon Signaling Defines the Proliferative Advantage of ARF and p53 Mutant Tumor Cells. Mol Cell Biol. 2025;45:246\u201361.","journal-title":"Mol Cell Biol"},{"key":"3580_CR43","first-page":"1352","volume":"24","author":"J Cui","year":"2025","unstructured":"Cui J, Zhang Y, Yang L. IFN-gamma in the tumor microenvironment: dual roles in cancer progression and therapy. EXCLI J. 2025;24:1352\u201371.","journal-title":"EXCLI J"},{"key":"3580_CR44","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10549-020-05646-x","volume":"181","author":"AI Aljohani","year":"2020","unstructured":"Aljohani AI, Joseph C, Kurozumi S, Mohammed OJ, Miligy IM, Green AR, et al. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. Breast Cancer Res Treat. 2020;181:541\u201351.","journal-title":"Breast Cancer Res Treat"},{"key":"3580_CR45","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1593\/neo.91110","volume":"11","author":"MF Calmon","year":"2009","unstructured":"Calmon MF, Rodrigues RV, Kaneto CM, Moura RP, Silva SD, Mota LD, et al. Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia. 2009;11:1329\u201339.","journal-title":"Neoplasia"},{"key":"3580_CR46","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.cell.2011.03.044","volume":"145","author":"AC Bester","year":"2011","unstructured":"Bester AC, Roniger M, Oren YS, Im MM, Sarni D, Chaoat M, et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell. 2011;145:435\u201346.","journal-title":"Cell"},{"key":"3580_CR47","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature23449","volume":"548","author":"KJ Mackenzie","year":"2017","unstructured":"Mackenzie KJ, Carroll P, Martin CA, Murina O, Fluteau A, Simpson DJ, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548:461\u20135.","journal-title":"Nature"},{"key":"3580_CR48","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/nrc.2016.82","volume":"16","author":"A Kinnaird","year":"2016","unstructured":"Kinnaird A, Zhao S, Wellen KE, Michelakis ED. Metabolic control of epigenetics in cancer. Nat Rev Cancer. 2016;16:694\u2013707.","journal-title":"Nat Rev Cancer"},{"key":"3580_CR49","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/ncb3629","volume":"19","author":"MA Reid","year":"2017","unstructured":"Reid MA, Dai Z, Locasale JW. The impact of cellular metabolism on chromatin dynamics and epigenetics. Nat Cell Biol. 2017;19:1298\u2013306.","journal-title":"Nat Cell Biol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03580-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03580-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03580-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:53:09Z","timestamp":1793890389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03580-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,11,20]]}},"alternative-id":["3580"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03580-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"24 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the Ethics Committee of Shanghai Outdo Biotech Co., Ltd. for the use of human tissue microarrays, and written informed consent was obtained from all participants. All animal experiments were approved by the Institutional Animal Care and Use Committee of the National Center for Protein Sciences (Beijing). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors have read and approved the final manuscript and agree to its submission for publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}